Orthofuse secures £2.2M seed to redefine safety in orthopaedic surgery

Orthofuse, an orthopaedic medtech company focused on delivering safer and more efficient surgical procedures, has closed a £2.2 million seed round. This funding, led by a group of angel investors with participation from ACF investors, Cambridge Angels, and Empirical Ventures, supports Orthofuse’s mission to develop 3D-printed implant systems that prioritise surgical ease of use and patient safety.

Orthopaedic trauma and spinal degenerative conditions often require procedures that are technically demanding, time-sensitive, and challenging when bone quality is poor. Current implant systems are often difficult to use consistently across varied clinical scenarios and cannot be repositioned without causing significant tissue damage. These limitations contribute to prolonged surgery times and increased risks for both patients and clinicians.

Orthofuse is developing a new generation of implants designed to improve the reversibility of procedures in challenging cases, simplify surgical procedures, and deliver better patient outcomes. By leveraging advanced additive manufacturing techniques and novel implant architectures, the company is creating solutions designed to reduce the number of surgical steps while ensuring strong fixation.

This investment will enable Orthofuse to advance its technical development, regulatory readiness, and to strengthen partnerships as it prepares for early-stage clinical evaluations.

James Scott, Co-Founder and CEO, Orthofuse, said: “Modern surgical practice demands implant systems that reflect the realities of the operating room. Orthofuse is developing a technology designed to simplify procedures, giving surgeons greater flexibility and confidence. This investment enables us to accelerate progress toward setting a new standard for safety and efficiency in orthopaedic care.”

Didier Cowling, Lead investor and Board Member, commented: “Orthofuse has reimagined the fundamental architecture of implants to solve the inefficiencies of current solutions. We believe this approach has real value in improving orthopaedic care, and are pleased to support the team as they move forward.”

See Also

Futurail raises €7.5M to bring autonomous trains on track

Tim Mills, Managing Partner, ACF Investors, said: “Orthofuse is tackling a critical challenge in surgery by coupling advanced engineering and clinical practicality. James and his team have developed a truly innovative approach to implant architecture that has the potential to significantly improve patient outcomes whilst enhancing surgical efficiency, and we are delighted to support them in this journey.”